RxDoctor Payments Data

George Madden, MD

Cardiovascular Disease · Oklahoma City, OKNPI 1548420722

Payments from drug & device makers

$4,378in general payments, 2019–2025

Across 237 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$566
  • Pfizer$538
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$383
  • AstraZeneca$380
  • Abbott$280
  • Novartis$275
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,378 in reported general payments places this provider in the 55th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$484,537
Medicare patients
2,282
Services billed
6,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,363$1,301,262
Repatha SureclickEvolocumab368$308,530
XareltoRivaroxaban243$238,075
EntrestoSacubitril/Valsartan137$164,519
JardianceEmpagliflozin123$97,929
FarxigaDapagliflozin Propanediol54$62,439
Praluent PenAlirocumab72$52,027
MultaqDronedarone Hcl44$49,864
VascepaIcosapent Ethyl44$25,467
Atorvastatin Calcium1,608$20,428
CorlanorIvabradine Hcl11$14,541
Repatha SyringeEvolocumab21$14,402
BrilintaTicagrelor15$14,294
Metoprolol Succinate1,102$11,282
Clonidine110$10,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$538$1,301,2621,363 claims
Johnson & JohnsonXarelto$272$238,075243 claims
NovartisEntresto$275$164,519137 claims
Boehringer IngelheimJardiance$35$97,929123 claims
AstraZenecaFarxiga, Brilinta$380$76,73369 claims
Sanofi-aventis U.S. LLCMultaq$59$49,86444 claims
AmgenCorlanor$135$14,54111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →